biomarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. we remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. these patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. these conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. time is critical to patients with rare diseases, and we strive to quickly develop important therapies for them. the efficiency and speed of our research, development, manufacturing, and commercial efforts is at the heart of our ability to urgently deliver therapies. our track record of developing and commercializing new treatment
Company profile
Ticker
BMRN
Exchange
Website
CEO
Jean-Jacques Bienaime
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
BioMarin Commercial Ltd • BioMarin International Ltd ...
IRS number
680397820
BMRN stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
9 Apr 24
DEFA14A
Additional proxy soliciting materials
9 Apr 24
DEF 14A
Definitive proxy
9 Apr 24
10-K
2023 FY
Annual report
26 Feb 24
8-K
BioMarin Reports Record Financial Results for the Fourth Quarter and Full-year 2023 and Provides Financial Guidance for 2024
22 Feb 24
8-K
Departure of Directors or Certain Officers
11 Jan 24
8-K
BioMarin Announces Governance Enhancements and Value Creation Initiatives
20 Dec 23
8-K
Departure of Directors or Certain Officers
3 Nov 23
S-8
Registration of securities for employees
2 Nov 23
10-Q
2023 Q3
Quarterly report
2 Nov 23
Transcripts
BMRN
Earnings call transcript
2023 Q4
22 Feb 24
BMRN
Earnings call transcript
2023 Q3
1 Nov 23
BMRN
Earnings call transcript
2023 Q2
31 Jul 23
BMRN
Earnings call transcript
2023 Q1
26 Apr 23
BMRN
Earnings call transcript
2022 Q4
28 Feb 23
BMRN
Earnings call transcript
2022 Q3
27 Oct 22
BMRN
Earnings call transcript
2022 Q2
4 Aug 22
BMRN
Earnings call transcript
2022 Q1
28 Apr 22
BMRN
Earnings call transcript
2021 Q4
24 Feb 22
BMRN
Earnings call transcript
2021 Q3
28 Oct 21
Latest ownership filings
4
JEAN JACQUES BIENAIME
15 Apr 24
4
Erin Burkhart
12 Apr 24
144
Notice of proposed sale of securities
12 Apr 24
144
Notice of proposed sale of securities
11 Apr 24
144
Notice of proposed sale of securities
10 Apr 24
4
George Eric Davis
1 Apr 24
144
Notice of proposed sale of securities
28 Mar 24
4
Dennis Slamon
20 Mar 24
4
Erin Burkhart
19 Mar 24
4
George Eric Davis
19 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
6.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 3 |
Opened positions | 0 |
Closed positions | 535 |
Increased positions | 1 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 1.21 bn |
Total shares | 12.94 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
CAFBX Amcap Fund | 10.18 mm | $866.57 mm |
Loomis Sayles & Co L P | 2.65 mm | $234.73 mm |
Comerica Bank | 109.00 k | $106.31 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Apr 24 | Jean Jacques Bienaime | Common Stock | Sell | Dispose S | No | Yes | 91.26 | 20,000 | 1.83 mm | 474,994 |
12 Apr 24 | Jean Jacques Bienaime | Common Stock | Option exercise | Acquire M | No | Yes | 63.1 | 20,000 | 1.26 mm | 494,994 |
12 Apr 24 | Jean Jacques Bienaime | Stock Option (Right to Buy Common Stock) Common Stock | Option exercise | Dispose M | No | No | 63.1 | 20,000 | 1.26 mm | 91,000 |
11 Apr 24 | Jean Jacques Bienaime | Common Stock | Sell | Dispose S | No | Yes | 90.99 | 20,000 | 1.82 mm | 474,994 |
11 Apr 24 | Jean Jacques Bienaime | Common Stock | Option exercise | Acquire M | No | Yes | 63.1 | 20,000 | 1.26 mm | 494,994 |
11 Apr 24 | Jean Jacques Bienaime | Stock Option (Right to Buy Common Stock) Common Stock | Option exercise | Dispose M | No | No | 63.1 | 20,000 | 1.26 mm | 111,000 |
10 Apr 24 | Erin Burkhart | Common Stock | Sell | Dispose S | No | Yes | 90 | 2,286 | 205.74 k | 16,156 |
28 Mar 24 | George Eric Davis | Common Stock | Sell | Dispose S | No | Yes | 88.34 | 24,602 | 2.17 mm | 55,856 |
18 Mar 24 | Slamon Dennis | Common Stock | Payment of exercise | Dispose F | No | No | 83.81 | 9,510 | 797.03 k | 31,299 |
18 Mar 24 | Slamon Dennis | Common Stock | Option exercise | Acquire M | No | No | 79.7 | 10,000 | 797.00 k | 40,809 |
News
Looking Into Biomarin Pharmaceutical's Recent Short Interest
3 Apr 24
New Data To Be Presented For BioMarin's VOXZOGO In Children With Hypochondroplasia And Achondroplasia At The American College Of Medical Genetics And Genomics Annual Clinical Genetics Meeting
12 Mar 24
Canaccord Genuity Reiterates Hold on Biomarin Pharmaceutical, Maintains $91 Price Target
29 Feb 24
BioMarin Complied With A U.S. Department Of Justice Subpoena For Documents On Its Testing Programs For VIMIZIM And NAGLAZYME; Cannot Predict Investigation's Outcome Or Its Impact On Its Business Or Financial Statements
26 Feb 24
The Latest Analyst Ratings For Biomarin Pharmaceutical
23 Feb 24
Press releases
BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET
10 Apr 24
New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
12 Mar 24
BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer
7 Mar 24
BioMarin Scheduled to Participate in March Investor Conferences
1 Mar 24
NorthStar Medical Technologies, LLC Announces Appointment of Barbara Bodem and David Keeling to Board of Managers
27 Feb 24